 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
19 News |  |
- | ivermectin oral / Generic mfg.
Journal: Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study. (Pubmed Central) - Dec 14, 2022
The results of molecular docking and MD simulation studies reveal that IDX184 is a stable molecule and forms strong interactions with the key amino acids and shows high binding affinity towards RdRp. Hence, IDX184 may also be considered as a potential inhibitor of RdRp after clinical study.Communicated by Ramaswamy H. Sarma.
- | Journal: Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an in silico perspective. (Pubmed Central) - May 25, 2022
Additionally, other compounds such as setrobuvir, YAK, IDX-184 and modified GTP compounds 2, 3 and 4 show potential calculated average binding affinities against R. oryzae RdRp. The present in silico study suggests the dual inhibition potential of the recommended drugs and compounds against SARS-CoV-2 and R. oryzae RdRps.
- || Sovaldi (sofosbuvir) / Gilead
Review, Journal: INSIGHTS INTO THE BIOLOGICAL IMPACT OF COVID-19 AND ITS VACCINES ON HUMAN HEALTH. (Pubmed Central) - Feb 22, 2022
Molnupiravir, an orally active RdRp inhibitor and noval broad spectrum antiviral agent, is an isopropyl pro-drug of EIDD-1931 for emergency use...Top seeds for antiviral treatments with high potential to combat the SARS-CoV-2 strain include guanosine derivatives (IDX-184), setrobuvir, and YAK. The goal of this review is to compile scattered information on available COVID-19 vaccines and other treatments for protecting the human body from their harmful effects and to provide options for making better choices in a timely manner.
- | hydroxychloroquine / Generic mfg., ribavirin / Generic mfg., cefuroxime / Generic mfg.
Journal: SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. (Pubmed Central) - Jun 22, 2021
Additionally, Setrobuvir, YAK, and IDX-184, show better results, while four novel IDX-184 derivatives show promising results in attaching to the SARS-CoV-2 RdRp...The availability of a punch of FDA-approved anti-viral drugs can help us in this mission, aiming to reduce the danger of COVID-19. The compounds 2 and 3 may tightly bind to the SARS-CoV-2 RdRp and so may be successful in the treatment of COVID-19.
- || Review, Journal: Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic. (Pubmed Central) - Jan 29, 2021
The other drugs such as favipiravir and lopinavir/ritonavir under the antiviral category, the angiotensin-converting enzyme 2 (the renin-angiotensin system inhibitors), remdesivir (RNA polymerase inhibitor) from antiviral category, cepharanthine from anti-inflammatory category, etc., have been pointed based on the previous literature published. Besides, the assessment of the drug repositioning candidates with the related targets is also significant for the viral mitigation.
- | IDX 184 / Merck (MSD), INX 189 / BMS
Journal: Intracellular metabolism and potential cardiotoxicity of a β-D-2'-C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication. (Pubmed Central) - Sep 24, 2020
Imaging data of drug treated human cardiomyocytes was found to be most useful in determining toxicity potential as no obvious beating rate change was observed for IDX-184 up to 50 µM up at 48 h. However, with BMS-986094 and DAPN-PD at 10 µM changes to both beat rate and rhythm were noted.
- | Journal: Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. (Pubmed Central) - Jun 9, 2020
The drugs mentioned above can tightly bind to the RdRp of the SARS-CoV-2 strain and thus may be used to treat the disease. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA.
- | Sovaldi (sofosbuvir) / Gilead
Journal: Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. (Pubmed Central) - Mar 28, 2020
The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
- |||| IDX 184 / Merck (MSD)
Trial completion, Trial primary completion date, Combination therapy: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) (clinicaltrials.gov) - Feb 6, 2015
P2, N=68, Completed, Sponsor: Merck Sharp & Dohme Corp.
Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection. Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Mar 2013
- || IDX 184 / Merck (MSD)
Trial primary completion date, Combination therapy: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) (clinicaltrials.gov) - Sep 5, 2014
P2, N=68, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Mar 2013 Trial primary completion date: Aug 2013 --> Oct 2014
- ||| IDX 184 / Merck (MSD)
Enrollment closed, Combination therapy: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) (clinicaltrials.gov) - Jul 4, 2012
P2, N=60, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Trial primary completion date: Aug 2013 --> Oct 2014 Recruiting --> Active, not recruiting
- ||| IDX 184 / Merck (MSD)
Enrollment change, Combination therapy: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) (clinicaltrials.gov) - Feb 7, 2012
P2, N=60, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting N=100 --> 60